Ms. Gibson is CEO and Co-Founder of Ariel Precision Medicine, an innovative precision medicine company, transforming genetic and clinical data into new insights for the diagnosis and therapeutic development of complex chronic conditions. She led the development, validation, and commercial launch of Advance®, Ariel’s AI-fueled platform, which has identified new therapeutic targets for complex pancreatic diseases. She served as Chief Commercial Officer of Ariel Precision Medicine until 2016, bringing over 15 years of experience in healthcare, Biotech and Pharma from previous roles at Purdue, Shionogi Pharmaceuticals, and Gene Wiz Inc.
She began her career working with the Center for Emergency Medicine, Gastroenterology research at the University of Pittsburgh, and research with the Cancer Institute.
Ms. Gibson earned an Executive MBA from Liberty University and a Bachelor of Science in Emergency Medicine from the University of Pittsburgh and a Certification in Disruptive Strategy from Harvard Business School.